Neurocrine partners with Mitusbushi Tanabe on neurological drug in Asia

1 April 2015

Neurological and endocrine specialist Neurocrine Biosciences (Nasdaq: NBIX) has entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe (TSE: 4508) for the development of NBI-98854 in Japan and other Asian markets.

Mitsubishi Tanabe intends to initially develop VMAT2 inhibitor NBI-98854 in Japan for the chorea associated with Huntington’s disease and tardive dyskinesia. Neurocrine will retain full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.

Financial terms of the deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK